Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

Safe Pro Group (NASDAQ: SPAI) announced that the recently enacted One Big Beautiful Bill Act (OBBBA), which allocates $33 billion in U.S. government spending for drones and AI, presents major growth opportunities for its AI-powered drone imagery analysis technology. The Company's SPOTD platform, which can detect over 150 types of explosive threats in real time, is already deployed in conflict zones like Ukraine and is being integrated into the U.S. Army's ATAK system. With $13.5 billion earmarked for unmanned systems and $16 billion for AI initiatives across defense and border operations, Safe Pro aims to expand its work with the Department of Defense and prime contractors as federal demand for advanced battlefield and homeland security tech accelerates.

To view the full press release, visit https://ibn.fm/lKBVb

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Wednesday's trading session at $2.94, up 22.5%, on 8,179 volume. The average volume for the last 3 months is 40,614 and the stock's 52-week low/high is $1.47/$6.4999.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - TechMediaBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Sees Growth Ahead with AI Drone Tech Following $33 Billion Federal Defense Bill 
• Safe Pro Group Inc. (NASDAQ: SPAI) Joins Russell Microcap(R) Index, Signaling Growing Investor Recognition, Market Visibility
• InvestorNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Joins Russell Microcap Index Following June Reconstitution

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet's Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities exceeding $2 billion across its pipeline. With approximately $7 million in cash and active exploration of partnerships and M&A, Soligenix aims to extend its cash runway into 1Q 2026 while preparing for global regulatory filings and potential commercialization.

To view the podcast, visit https://ibn.fm/dQUKU

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Wednesday's trading session at $1.25, up 2.459%, on 7,824 volume. The average volume for the last 3 months is 2,145,607 and the stock's 52-week low/high is $1.09/$9.78.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025-2026 Catalysts Across Rare Disease Pipeline
• Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
• InvestorNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company focused on treating primary and metastatic cancers in the brain and central nervous system, announced CEO John Climaco's participation in a Virtual Investor CEO Connect segment. Climaco provided an overview of the Company's lead candidate, TPI 287, and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, Massachusetts.

To view the full press release, visit https://ibn.fm/gk4UG

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.94, up 2.9911%, on 6,947 volume. The average volume for the last 3 months is 207,622 and the stock's 52-week low/high is $0.7303/$82.5.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment 
• TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar 
• BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)

The QualityStocks Daily Newsletter would like to spotlight LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF).

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) has engaged Bumigeme Inc. to conduct an independent valuation report of its fully owned Beacon Gold Mill in Val-d'Or, Québec. The report will assess replacement value and restart costs for the mill and tailings facility, which received over $20 million in upgrades in 2022. The valuation aims to support financing efforts and highlight the company's potential to monetize production at the Beacon Mill, tied to the Swanson Gold Project. LaFleur Minerals is preparing for gold production and a Preliminary Economic Assessment while leveraging favorable market conditions, including J.P. Morgan's forecast of $4,100 gold in 2026.

To view the full press release, visit https://ibn.fm/jphTm

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is a Canadian exploration and development company advancing the district-scale Swanson Gold Project in Québec’s prolific Abitibi Gold Belt and progressing toward the near-term restart of gold production at its wholly owned Beacon Gold Mill. The company’s strategy centers on consolidating strategic land packages—highlighted by its flagship Swanson Gold Project, a 160 km² district-scale property that includes several prospects rich in gold and critical metals previously held by Monarch Mining, Abcourt Mines, and Globex Mining. The company is leveraging its 100%-owned, fully permitted and recently refurbished Beacon Gold Mill to transition from explorer to near-term gold producer—a key inflection point that typically triggers a market re-rating, further bolstered by current rising gold market prices. By processing material from Swanson and offering custom milling to regional projects, LaFleur aims to generate cash flow with minimal capital outlay, targeting annual gold production of up to 15,000 to 20,000 ounces by early 2026.

LaFleur’s vision is to evolve into an intermediate gold producer by capitalizing on strong market conditions and Québec’s rich mining infrastructure. The location, in the world-class Abitibi Gold Belt, and its infrastructure advantage, positions LaFleur for regional consolidation, strategic partnerships, or acquisition interest. Its mission emphasizes efficient value creation through methodical exploration, low-cost asset advancement, and opportunistic acquisitions—including land and deposits from Monarch Mining, Abcourt Mines, and Globex Mining.

Québec ranks among the world’s top mining jurisdictions, offering access to flow-through capital and regulatory stability. LaFleur’s integrated strategy—combining exploration at Swanson, a permitted mill at Beacon, and potential custom milling agreements—supports a streamlined path to near-term production.

LaFleur Minerals is headquartered in Vancouver, British Columbia.

Projects

LaFleur Minerals’ operations focus on two strategically located assets in the Abitibi Gold Belt: the Swanson Gold Project and the Beacon Gold Mill and Mine. These projects leverage the region’s world-class mining infrastructure and high-grade gold potential to drive the company’s transition to production.

Swanson Gold Project

The Swanson Gold Project spans 16,600 hectares and hosts the Swanson, Bartec, and Jolin gold deposits along a major structural break in the Abitibi Gold Belt. The 2024 Mineral Resource Estimate for the Swanson deposit outlines 123,400 oz of gold in Indicated category (2.1 million tonnes at 1.8 g/t) and 64,500 oz in Inferred category (872,000 tonnes at 2.3 g/t). Located 66 km north of Val-d’Or, the Project is accessible by road and rail and benefits from more than 36,000 meters of historical drilling, along with existing infrastructure including an 80-meter decline portal.

Recent work—including airborne magnetics, soil sampling, and Induced Polarization surveys—has identified multiple high-priority targets and resulted in several high-grade gold assay results, including a grab sample grading 11.71 g/t Au at Jolin, which points to significant upside as the Company prepares to test multiple new zones.

LaFleur has defined over 50 drill targets at Swanson and nearby prospects (Bartec, Jolin, Marimac) and is completing a minimum 5,000-metre diamond drilling beginning in June 2025. LaFleur Minerals has also initiated permitting for a 100,000-tonne surface bulk sample averaging 1.89 g/t Au, which it plans to process at the Beacon Gold Mill as part of a near-term production strategy.

Beacon Gold Mill

LaFleur’s 100%-owned Beacon Gold Mill is a fully refurbished and permitted mill and tailings storage facility capable of processing 750 tonnes per day (tpd), with potential expansion to 1,800 tpd, with access to numerous nearby gold deposits that could be prime sources of ore. Located only 60 km from Swanson, it underwent a $20 million upgrade by Monarch Mining in 2022 and has been under care and maintenance since early 2023. LaFleur is finalizing a C$5-6 million restart plan, ramping up production by late 2025 into early 2026, processing Swanson mineralized material and assessing custom milling opportunities for regional deposits, creating multiple potential revenue streams.

The Beacon Gold Mill is a de-risked, proven asset that benefits from existing infrastructure, including access to roads, power, and skilled labor, and further enhances the overall value proposition of LaFleur by providing a clear path to production and potential revenue-generation.

Market Opportunity

LaFleur Minerals is targeting the gold mining and processing market in Québec’s Abitibi Gold Belt, one of the world’s most productive gold regions. Its fully permitted Beacon Gold Mill, with a 750 tpd capacity and authorization to process 1.8 million tonnes of tailings, is strategically positioned to handle material from LaFleur’s Swanson Gold Project and to offer custom milling for nearby deposits such as Granada Gold. The company projects annual production of over 30,000 ounces of gold once in full production, with potential for significant revenue generation based on prevailing market prices.

Global demand for gold remains robust, driven by geopolitical risk, inflation hedging, and central bank accumulation. The World Gold Council forecasts 3-5% annual demand growth through 2030, with average prices expected between $3,200 and $3,500/oz. Within this environment, Québec’s top-tier mining jurisdiction—ranked fifth globally by the Fraser Institute in 2023—offers streamlined permitting and access to flow-through capital. LaFleur’s low-cost Beacon restart (C$5-6 million) and proximity to more than 100 active and historical mines position the company to fill a growing need for small-to-medium scale custom milling.

At Swanson, LaFleur plans to grow its current 187,900-ounce resource toward 1 million ounces through its 2025 drilling program. This hub-and-spoke strategy, leveraging centralized milling and strong local infrastructure, reduces development risk and strengthens LaFleur’s foothold in one of the most attractive gold belts in the world.

Leadership Team

Kal Malhi, Chairman, is a successful entrepreneur and the Founder of Bullrun Capital Inc., where he has raised over $300 million for early-stage companies across the mining, oil and gas, biomedical, agriculture, and technology sectors. He specializes in advancing academic research into commercial ventures and public listings, with more than two decades of capital markets and leadership experience.

Paul Ténière, M.Sc., P.Geo., Chief Executive Officer, is a seasoned mining executive and Professional Geologist with over 25 years of global experience in the development of precious and base metals, critical minerals, and metallurgical coal projects. Mr. Ténière is an expert in NI 43-101 and S-K 1300 disclosure standards and has held senior roles including President & CEO, SVP Exploration, and Director with several publicly traded mining companies. Mr. Ténière also worked at the Toronto Stock Exchange (TSX) and TSX Venture Exchange as a mining expert and Senior Listings Manager listing dozens of mining companies and ensuring listed issuers met their corporate governance and compliance and disclosure requirements.

Harry Nijjar, Chief Financial Officer and Corporate Secretary, serves as Managing Director at Malaspina Consultants Inc., providing CFO and strategic financial advisory services to companies across multiple industries. He holds a CPA CMA designation from the Chartered Professional Accountants of British Columbia and a Bachelor of Commerce from the University of British Columbia.

Louis Martin, P.Geo., Technical Advisor and Exploration Manager, is a veteran geologist with more than 40 years of exploration experience. He has played key roles in significant gold and base metal discoveries, including the Louvicourt (1989) and West Ansil (2005) deposits—both recognized by the Association de l’Exploration Minière du Québec (AEMQ). He previously served as VP Exploration at Clifton Star Resources, where he led the pre-feasibility study for the 4.5 million-ounce Duparquet Gold Project. He is a registered geologist in Québec and Ontario.

Tara Asfour, Corporate Communications, Investor Relations and Strategy, is an experienced executive consultant with over 12 years of management, investor relations, communications and marketing experience, specialized in capital markets. In her previous positions, Ms. Asfour has led over US$550 million worth of fundraising and strategic development initiatives. Ms. Asfour holds a Master’s degree in Business Management, a Financial Markets Certificate from Yale University, and a Certificate in Alternative Investments from HBS. Previous positions include investor relations executive at Red Pine Exploration, Fancamp Exploration, Communications Director at Dominion Water Reserves (now Prime Drink Group Corp) and advisor to various other publicly listed firms in the resource and technology sectors. Ms. Asfour holds the Institute for Governance (IGOPP) Certification in Governance, Ethics in Business Environment and Corruption Prevention.

Peter Espig, Strategic Advisor and Consultant, has served as Vice-President at Goldman Sachs Japan in both the Principal Finance and Securitization Group and the Asia Special Situations Group, where his team participated in more than $10 billion in structured deals, capital raises, and cross-border transactions. Prior to Goldman Sachs, he was Vice-President at Olympus Capital, a New York-based private equity firm, where he focused on corporate restructurings, investment analysis, and international financing negotiations. He also played a pioneering role in some of the earliest SPAC transactions, totaling over US$1.2 billion, and brings deep experience in disciplined capital deployment and turnaround execution. Since 2013, Mr. Espig has served as President and CEO of Nicola Mining Inc. and is a board member of ESGold Corp and First Lithium Minerals. Mr. Espig holds a Bachelor of Arts from the University of British Columbia and an MBA from Columbia Business School, where he was a Chazen International Scholar. He has served on various public boards and was recognized among Industry Era’s “Top 10 Admired Leaders” in 2023.

Jean Lafleur, Senior Technical Advisor, is a Professional Geologist (Québec) with 45 years of experience in Canada and internationally including USA, Mexico, Latin America, Ireland, Spain and Africa. Earlier in his career he worked with Newmont, Falconbridge, Dome Mines, and Placer Dome and has been a C-suite executive for a number of junior exploration companies. Jean has remained active as a technical, management, and financing consultant with junior explorers since the early 2000’s through his own geological consultancy firm and throughout his career has led a number of teams in the discovery of precious and base metals, nickel, PGE’s, uranium, and iron deposits. Jean’s expertise includes mining company and project evaluations, audits, technical reporting, exploration program planning and execution, and research and development with a strong focus on Québec. Jean currently acts as a Senior Consultant, North America for Appian Capital Advisory LLP, a mining-focused private equity firm based in London, UK where through his extensive professional network he sources and presents potential mining transactions in North America to the Appian team for investment opportunities.

LaFleur Minerals Inc. (OTCQB: LFLRF), closed Wednesday's trading session at $0.3967, up 14.9522%, on 62,385 volume. The average volume for the last 3 months is 208,720 and the stock's 52-week low/high is $0.0139/$1.65.

Recent News

• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) - RockBreaks - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Commissions Valuation to Advance Beacon Gold Mill Restart
• InvestorNewsBreaks - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Featured in NetworkNewsAudio as It Advances Toward Production in Abitibi Gold Belt 
• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Moves Toward Beacon Gold Mill Restart and Bulk Sampling at Swanson Project

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF)

The QualityStocks Daily Newsletter would like to spotlight Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF).

Nicola Mining (TSX.V: NIM) (FSE: HLIA) (OTCQB: HUSIF) has commenced gold and silver concentrate production at its Merritt Mill in British Columbia, transitioning from trial processing to long-term operations. This milestone follows the receipt of a 3,100-tonne high-grade ore shipment from Talisker Resources Ltd. (TSX: TSK) (OTCQX: TSKFF), which is advancing development at its Mustang Project. Nicola's upgraded mill features automation, gravity separation and water recirculation systems. The company has also partnered with Blue Lagoon Resources (CSE: BLLG) (OTCQB: BLAGF) (FSE: 7BL) and is preparing to process bulk samples from the Dominion Creek Gold Project, where it holds a 75% economic interest. CEO Peter Espig emphasized the strategic value of Nicola's M-68 Mine Permit and British Columbia's support for responsibly managed mining ventures.

To view the full interview, visit https://ibn.fm/N7jZP

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade mineral assets in British Columbia. With a unique dual-pronged model, the company combines solid operational revenues from its wholly-owned, state-of-the-art gold and silver mill with the long-term upside of 100%-owned copper, silver, and gold exploration projects. This approach allows Nicola to fund ongoing development while minimizing equity dilution.

The company’s strategy centers on aligning infrastructure and permitting advantages with mineral-rich geology, positioning it to process its own, as well as third-party high-grade gold and silver mines via partnerships, to advance its own exploration targets. Key agreements with gold producers and concentrating sales contracts provide stable cash flow, making Nicola rare among juniors in its ability to internally support growth. Its solid balance sheet and business acumen have allowed it to take stakes in other near-term gold producers, including a 75% economic stake in Dominion Gold, which commences a bulk sample in 2H 2025.

Nicola is leveraging its platform of permitted infrastructure, strategic project locations, and deep technical expertise to build shareholder value in a low-risk, high-reward framework. The company is headquartered in Vancouver, British Columbia.

Projects

Nicola Mining’s project portfolio includes high-grade copper, silver, and gold assets located in mineral-rich regions of British Columbia. Each project is 100%-owned or majority-controlled, with strong exploration potential and the necessary permits to advance development.

New Craigmont Copper Project

Nicola’s flagship asset, the New Craigmont Project, is a historic producer of over 900 million pounds of copper. Since acquiring 100% ownership in 2015, the company has drilled over 18,000 meters and identified significant skarn-hosted and porphyry-style mineralization. Recent drilling in 2024 confirmed 52.9 meters at 1.03% Cu (Hole NC-24-002), supporting the presence of a large-scale copper system. The project benefits from paved road access, connection to BC Hydro’s grid, and proximity to urban centers.

Treasure Mountain Silver Project

This 100%-owned past-producing mine has a Major Mines permit (M-239) and an NI 43-101 compliant resource estimate. The site includes multiple silver-lead-zinc veins and is permitted to extract up to 60,000 tonnes annually. Nicola is evaluating potential reactivation or joint venture options. Resource estimates include indicated resources of 52,000 tonnes grading 18.1 oz/t Ag, 3.26% Pb, and 3.4% Zn, and inferred resources of 161,000 tonnes grading 22.0 oz/t Ag, 2.48% Pb, and 3.86% Zn.

Dominion Creek Project (Au-Ag)

Nicola holds a 50% land ownership and 75% economic stake in this gold-silver project. Located 43 km from Wells, British Columbia, the site has returned grab samples averaging 61.3 g/t Au and 173.7 g/t Ag. The company has received its final permit and plans to extract a 10,000-tonne bulk sample in 2025, which will be processed at its Merritt Mill facility.

Operations

In addition to its exploration assets, Nicola Mining operates a suite of permitted industrial facilities in British Columbia that generate revenue and support the company’s broader development strategy. These assets form the backbone of Nicola’s self-sustaining business model.

Merritt Mill & Tailings Facility

Nicola owns and operates British Columbia’s only provincially permitted toll mill for gold and silver, a $30 million flotation facility located near Merritt. Gold production began in 2023. The facility is supported by long-term Milling and Profit Share Agreements with companies including Osisko Development Corporation, Blue Lagoon Resources, and Talisker Resources.

Sand & Gravel Pit / Rock Quarry / Ready-Mix Concrete Plant

Nicola also operates a permitted gravel pit (100,000 t/year), rock quarry (1,500 t/day), and is set to launch a ready-mix cement plant in Q2 2025. These operations, run in partnership with local First Nations, generate stable cash flow to support exploration efforts.

Market Opportunity

Nicola Mining is uniquely positioned in southern British Columbia, a jurisdiction recognized for its mining-friendly policies, skilled labor force, and robust infrastructure. The New Craigmont Project is geologically situated within the Guichon Creek Batholith, a region hosting some of Canada’s largest copper mines, including Highland Valley. Exploration data from 2023 and 2024 support the potential presence of both skarn and porphyry systems, increasing the strategic value of Nicola’s holdings.

The company’s other assets, including Treasure Mountain and Dominion Creek, are located in historically productive areas with high-grade mineralization and established access routes. Dominion Creek, in particular, sits atop the Isaac Lake Fault system—identified in British Columbia’s RGS (Regional Geochemical Survey) as a highly anomalous gold-silver corridor. Nicola’s integrated production model enables it to generate revenue while advancing these exploration programs without excessive dilution, providing a distinct advantage in a volatile commodities market.

Leadership Team

Peter Espig, Chief Executive Officer & Director, is a former diamond driller who spearheaded Nicola through a restructuring into its recent growth. He brings over $2 billion in private equity transaction experience, is a pioneer of SPACs, and has held senior positions at Goldman Sachs Japan and Olympus Capital.

Will Whitty, VP of Exploration, brings to the company over 15 years of experience in copper and gold exploration. He previously worked at Freeport-McMoRan and Nevada Gold Mines. He holds a master’s degree from the Mineral Deposit Research Unit (MDRU) at the University of British Columbia.

Bill Cawker, Corporate Development, manages investor relations, communications, and corporate governance. He joined Nicola in 2023 and brings extensive small-cap public markets experience, along with a degree in economics from the University of British Columbia.

Sam Wong, Chief Financial Officer, is a CPA with over 18 years of experience in the mining sector. He previously held executive roles at several publicly listed resource companies. He began his career at Deloitte LLP in Vancouver.

Nicola Mining Inc. (OTCQB: HUSIF), closed Wednesday's trading session at $0.4748, up 1.3274%, on 5,731 volume. The average volume for the last 3 months is 84,740 and the stock's 52-week low/high is $0.1498/$0.5.

Recent News

• Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) - InvestorNewsBreaks - Nicola Mining Inc. (TSX.V: NIM) (FSE: HLIA) (OTCQB: HUSIF) Begins Long-Term Gold, Silver Production at Merritt Mill 
• RockBreaks - Powering AI: Nicola Mining Inc.'s (TSX.V: NIM) (OTCQB: HUSIF) Copper Project Aligns with Data Center Surge
• MiningNewsBreaks - Nicola Mining Inc. (TSX.V: NIM) (FSE: HLIA) (OTCQB: HUSIF) Begins AI-Enhanced Drill Program at New Craigmont Copper Project

Adageis

The QualityStocks Daily Newsletter would like to spotlight Adageis

Adageis was featured in a recent article that discussed its powerful and patented AI-centric software solution. "Healthcare is a complicated place, and navigating the system is extremely difficult for patients," Adageis' CEO Shane Speirs was quoted as saying. "What Adageis does is provide a simple solution to healthcare organizations, ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with."

To view the full article, visit https://ibn.fm/KM5fB

Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative solutions. By integrating artificial intelligence (AI) and machine learning, Adageis addresses inefficiencies in healthcare delivery, enabling providers to enhance patient outcomes and streamline operations. The company focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector.

With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training. This approach reduces barriers to adoption and helps healthcare organizations maximize their potential in an increasingly complex industry landscape.

Recent collaborations, including its partnership with HealthyU Clinics and integration with AthenaHealth as a marketplace partner, underscore Adageis’s industry relevance and adaptability.

Adageis is headquartered in Mesa, Arizona.

Services

Adageis offers the ProActive Care Platform, an AI-driven solution designed to integrate seamlessly with existing Electronic Medical Records (EMR) systems.

This platform enables healthcare providers to deliver patient-centric care while maximizing reimbursements from quality metrics and value-based contracts. Key features include:

• Predictive Analytics: Utilizes AI to analyze patient data, identifying high-risk individuals and care gaps to improve health outcomes and reduce costs.
• Efficiency and Cost Reduction: Continuously monitors patient health, allowing providers to offer proactive care even outside traditional office visits, thereby enhancing efficiency and lowering expenses.
• Flexible Integration: Compatible with various EMR systems, including AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, facilitating easy adoption without the need for extensive staff training or platform changes.

Market Opportunity

The global AI in healthcare market is experiencing rapid growth, driven by the increasing demand for enhanced efficiency, accuracy, and better patient outcomes. In 2023, the market was valued at approximately $19.27 billion by Grand View Research, and it is projected to grow at a compound annual growth rate of 38.5% from 2024 to 2030. This growth is fueled by the increasing need for solutions that can analyze large datasets, reduce costs, and improve care delivery across the healthcare continuum.

Adageis is well-positioned to capitalize on these trends. Its ProActive Care Platform offers AI-driven predictive analytics and proactive care solutions that align with the industry’s shift toward value-based care. By providing seamless integration with existing EMR systems and focusing on operational efficiency, Adageis enables healthcare providers to meet the demands of a rapidly evolving market.

Leadership Team

Shane Speirs, MD, MBA serves as the company’s CEO. He is a board-certified physician in family and geriatric medicine with extensive experience in healthcare leadership, data modeling, and AI applications in healthcare delivery. He holds an MBA in Healthcare Management from the W.P. Carey School of Business and has a proven track record in managing telehealth and AI-focused healthcare companies.

Bill Jentarra, MBA is the CTO of Adageis, bringing over 25 years of experience in architecting and implementing complex client relationship management (CRM) and business intelligence (BI) solutions across various industries, including healthcare. His expertise encompasses the entire lifecycle of CRM and BI projects, ensuring practical and cost-effective technology applications to solve complex business problems.

Recent News

• Adageis - AINewsBreaks – Adageis’ Platform Tackles Healthcare Complexities with AI
• Adageis: An AI-Powered Advocate for Healthcare Providers
• BioMedNewsBreaks — Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

ONAR Holding Corp. (OTCQB: ONAR)

The QualityStocks Daily Newsletter would like to spotlight ONAR Holding Corp. (OTCQB: ONAR).

ONAR's network of technology-first agencies focuses on data-driven strategy and execution over flashy, reactive campaigns

The company's proprietary AI platform Cortex drives results across integrated performance media, SEO, and industry-specialized marketing

Recent industry studies show that sustainable growth in marketing is increasingly tied to strategic consistency and AI integration

For years, speed was king in digital marketing. Agencies raced to deploy campaigns, iterate quickly, and exploit trends before they faded. But in 2025, this "move fast and break things" mindset is showing its limits. The rise of AI and the complexity of today's customer journeys require more than just agility; they demand a strategic foundation that connects data, technology, and creativity in a measurable way. Recent data supports this shift. According to a 2024 McKinsey study, companies that embed AI into end-to-end marketing operations grow revenue two to three times faster than those relying on point solutions or speed-based experimentation. That shift is giving rise to a new class of agencies focused less on speed for speed's sake and more on cohesive systems that deliver reliable results. One such firm leading this evolution is ONAR Holding Corp, (OTCQB: ONAR).

ONAR Holding Corp. (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

• Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
• Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
• CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
• ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

ONAR Holding Corp. (OTCQB: ONAR), closed Wednesday's trading session at $0.051, even for the day, on 13 volume. The average volume for the last 3 months is 5,580 and the stock's 52-week low/high is $0.03/$0.167.

Recent News

• ONAR Holding Corp. (OTCQB: ONAR) - ONAR Holding Corp. (ONAR): In Marketing's AI Era, Strategy is Beating Speed
• TechMediaBreaks - ONAR Holding Corp. (OTCQB: ONAR) Details Q1 Growth, Strategic Focus in Shareholder Letter 
• ONAR Holding Corp. (ONAR): Why Smart Agencies Are Choosing Algorithms Over Assumptions

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ).

A report from the Federal Reserve Bank of Dallas has revealed that there was a slight contraction in oil and gas activity in New Mexico, Texas, and Louisiana as companies reacted to an increase in steel tariffs. The Dallas Fed survey found that the current administration's tariff war with China and several other nations is already having a tangible effect on America's oil and gas industry. This fall in activity comes after President Donald Trump doubled  import tariffs on aluminum and steel from 25% to 50% early last month, making it more expensive for companies to import steel and aluminum into the country. With 50% of all the aluminum and a quarter of the steel used in the country being imported, the Trump administration's import tariffs have had a sweeping effect across American industry. If these tariffs remain in place, they could further dampen drilling activity and raise costs for domestic producers. Without policy revisions or support, the U.S. oil and gas sector may struggle to remain competitive, especially as global markets shift and production strategies evolve. For U.S. energy firms like GEMXX Corp. (OTC: GEMZ) with a focus on exploring for oil and gas resources in Latin America, the option available now is to source the imports they need directly into the Latin American countries where they have operations since costs would become inflated if those inputs go through the U.S. 

GEMXX Corp. (OTC: GEMZ), a publicly traded company established as a mine-to-market gold, gemstone and jewelry producer, is now expanding into energy projects and has positioned itself to be a significant player in the energy market with a focus on investment in Latin America’s oil and gas sector. Established with a vision to capitalize on untapped and emerging opportunities, the company specializes in identifying and executing projects with the potential of extraordinary returns.

GEMXX (and its partners) are led by seasoned experts with decades of collective experience in the energy industry. GEMXX leverages cutting-edge technology, strategic partnerships and rigorous market analysis to pinpoint lucrative ventures in Latin America’s dynamic energy landscape. Central to the company’s mission is its commitment to investing in overlooked, low-cost, high return oil and gas exploration projects. By meticulously assessing geological data, geopolitical factors and market trends, GEMXX identifies regions with the greatest potential for significant undiscovered reserves and optimal extraction conditions.

The company’s strategic geographic focus on Latin America allows it to capitalize on the region’s vast reserves while navigating regulatory frameworks to foster mutually beneficial relationships with local stakeholders. Through a combination of innovation, expertise and unwavering dedication, GEMXX aims to redefine the possibilities in Latin America’s oil and gas sector.

The company is headquartered in Las Vegas.

Projects and Operations

Energy Investments

GEMXX is strategically expanding its business model to include a significant partnership with Latin Energy Partners Inc. LEP is actively exploring two basins in Latin America, with estimates indicating a potential for over 1 billion barrels of recoverable oil in each basin.

The two companies have defined terms to jointly drill four test wells in a promising geological formation in the Republic of Paraguay. GEMXX’s investment secures 40% of production from the first four wells and 40% of future production from nearly 25,000 acres surrounding the initial test well heads.

Seismic and geological data assessments show promising indicators for hydrocarbon deposits. Initial exploration of the two target basins confirmed several kilometers of sedimentary fill with strong potential for accommodating successful, conventional oil and gas petroleum systems.

Latin America remains largely uncharted in hydrocarbon exploration, yet recent studies suggest considerable untapped potential. GEMXX believes Latin America is one of the last underdeveloped energy opportunities on Earth, quickly emerging due to demand and deregulation.

Market Opportunity

A 2023 report from ReportLinker, an award-winning market research company, estimated the value of the global oil and gas market that year at $7.33 trillion and projected it would grow to $8.67 trillion by 2027, representing a CAGR of 4.3% over the forecast period.

The report identified the ongoing Russia-Ukraine war, with its resulting economic sanctions and supply chain disruptions, as a constraint on market expansion that will hold market growth below its natural level. Oil price volatility is also likely to have a negative impact on market growth, according to the report. In May 2024, the market price of crude oil was approximately $78 per barrel.

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council. In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

Richard Clowater is Chairman and CEO of GEMXX. His experience spans several industries, including but not limited to oil and gas, mining, gemstone manufacturing, industrial and commercial construction. He has worked throughout North America, the Middle East and Africa. He has been Vice President of Sales and Marketing at Korite International and Technical Sales Manager for Tarpon Structures. He also held the position of Regional Manager for Newalta, an environmental services company, where he oversaw operations for three divisions.

Deane Preston is Director of GEMXX. He brings a wealth of experience and expertise in electrical infrastructure planning, installation and management. He previously served as Operations Manager at Northern Wasco County Public Utility District in Oregon. Prior to that, he served as an Electrical Technician/Manager at Florida Power and Light in South Florida.

GEMXX Corp. (OTC: GEMZ), closed Wednesday's trading session at $0.0064, even for the day, on 50,948 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.001/$0.03.

Recent News

• GEMXX Corp. (OTC: GEMZ) - Oil, Gas Activity Reduced in Q2 Amid Tariffs, Survey by Dallas Fed Shows 
• Why Global Oil and Gas Prices Remained Largely Unchanged During the Israel-Iran War
• Global Trade in Oil, Gas Could Be Rattled by Iran 

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Electric vehicles, or EVs, are not just changing how we drive; they are changing how cars are built and look. The shift from gas-powered engines to electric motors has opened up a world of new ideas for designers and engineers. Without the need for bulky engines or exhaust systems, car makers are rethinking every part of the vehicle. One of the biggest changes is the use of the "skateboard chassis." This is a flat platform that holds the battery and electric motors. It's like a base that different types of cars, like sedans, pickups, or SUVs, can be built on. Because of this, manufacturers can now create many kinds of vehicles using the same basic structure. It also means designers have more freedom to play with the car's shape and features. Around the world, countries are showing different styles of EV design. In Europe, small and simple EVs are popular in cities. In China, there's a wide mix of tiny budget cars and futuristic luxury models. And in the U.S., bold designs like the Tesla Cybertruck are gaining attention. Overall, EVs are giving the auto industry a fresh start. With new shapes, smarter systems, and more creative ideas, electric cars are driving a true revolution in how vehicles are made and experienced. We can only watch and wait for what new EV designs and features startups like Mullen Automotive Inc. (NASDAQ: MULN) will unveil in the models they release as the years go by. 

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with United States-based manufacturing located in Tunica, Mississippi.

In August 2023, Mullen began commercial vehicle production in Tunica. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Mullen Automotive. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

Mullen Commercial

Mullen is defining a new era in commercial vehicles with its connected and customized solutions aimed at making businesses more efficient and profitable.

Mullen ONE Class 1 EV Cargo Van

The Mullen ONE class 1 commercial electric vehicle is the first of its kind in the U.S. market. This van was designed to navigate within narrow urban streets and residential roads, all while maximizing payload and cargo space. The Mullen ONE’s height is less than 6.5 feet, meaning your driver can park the vehicle in a residential garage.

Mullen THREE Class 3 Electric Truck

The efficient urban utility low cab forward features a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. Even in reverse, maneuverability is a breeze with our standard backup camera and 7-inch display screen. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,300 lbs of payload. In addition, the design of the LCF chassis allows more cargo length within a given overall length.

Mullen Commercial EVs are eligible for several federal and state level EV incentives, which can be combined for maximized savings.

Mullen ONE:

• $7,500 Federal Tax Credit
• $3,500 MOR-EV Incentive (Massachusetts only)
• $7,500 ComEd Business & Public Sector EV Rebate Program (Illinois only)

Mullen THREE:

• $7,500 Federal Tax Credit
• $45,000 California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) (California only)
• $15,000 MOR-EV Incentive (Massachusetts only)
• $30,000 ComEd Business & Public Sector EV Rebate Program (Illinois only)

In the last two years, Mullen has conducted over 100 vehicle demos or pilots across various industries in the U.S. resulting in significant progress, including new sales opportunities and vehicle orders received and or completed:

• Universities: Princeton University, University of Virginia (UVA), University of California, Los Angeles (UCLA)
• Local city governments: Cities of Dublin, Ohio, Raleigh, North Carolina, Los Angeles, California, Seattle, Washington and Orange County, North Carolina
• Small businesses: From local florist shops to health care providers delivering supplies

Mullen has an extensive dealer network in the U.S. with renowned dealers nationwide including:

• Papé Group (California, Oregon, Washington)
• National Auto Fleet Group (California)
• Pritchard EV (Iowa)
• Eco Auto (Massachusetts)
• Ziegler Truck Group (Minnesota)
• Range Truck Group (Washington)
• Mullen Commercial Vehicle Center (California)

Mullen Commercial EVs are available for purchase on Sourcewell under NAFG’s Sourcewell Contract # 091521-NAF which offers Class 1-3 light duty trucks, cars, vans, SUVs, cab chassis, and electric vehicles with related equipment and accessories to U.S. government agencies.

Bollinger Motors

Mullen entered the medium-duty truck classes through its September 2022 acquisition of a controlling interest in EV truck innovator Bollinger Motors. The acquisition gave Mullen access to a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets, such as last-mile delivery, refrigeration, utilities and upfitters.

The 2025 Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger’s unique chassis design protects the 158-kWh battery pack and components to offer unparalleled capability and safety in the commercial market. The vehicle also features a payload in excess of 7,300 pounds with an average driving range of 185 miles. Bollinger Motors began serial production of the B4 on Sept. 16 via its manufacturing partnership with Roush Industries at their facility in Livonia, Michigan.

Bollinger Motors has passed numerous milestones in recent months, including:

• 30 B4s delivered and paid for, worth nearly $4.5 million, since start of production
• Its production launch on Sept. 16 at Roush Industries in Livonia, Michigan
• Achieving FMVSS compliance
• Receiving the Certificate of Conformity from the Environmental Protection Agency, and CARB certification
• The creation of a world-class dealer and service network
• An agreement with Our Next Energy in Novi, Michigan, for battery packs
• Providing a full warranty coverage of the B4 chassis cab
• Announcing Syncron as its warranty administration partner and Amerit Fleet Solutions as its mobile service provider
• A partnership with EO to power EV charging infrastructure, equipment and technology solutions for Bollinger’s dealers and customers

Bollinger Motors has qualified for multiple federal and state incentive programs, including:

• Inflation Reduction Act incentives of up to $40,000 per vehicle
• California: Innovative Small e-Fleet (ISEF) Pilot Program, with incentives up to $120,000 per vehicle
• Massachusetts: voucher of up to $30,000 per vehicle from Massachusetts Offers Rebates for Electric Vehicles (MOR-EV)
• New York: up to $100,000 from NYTVIP through NYSERDA
• Pennsylvania: up to a $20,000 grant from Alternative Fuels Incentive Grant Program (AFIG) of the Pennsylvania Department of Environmental Protection

Mullen FIVE RS

The Mullen FIVE RS is an ultra-high-performance EV Crossover featuring a top speed of over 200 mph and acceleration from 0-60 mph in under 2 seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, two-speed gearbox, and over 1,100 horsepower.

The Mullen FIVE RS is planned for launch in Germany with vehicle sales planned for December 2025. Initial vehicle market territories include the EU in 2025, followed by the UAE and South Africa in early 2026.

Mullen is partnering with Faissner Petermeier Fahrzeugtechnik AG (“FPF”), which has decades of experience in the development and production of serial components and sophisticated vehicles for global brands such as Piech Automotive, Gumpert Automotive and is in partnership with BMW of all the above. FPF is certified according to the IATF standard and fulfills all the special requirements of the Federal Motor Transport Authority in Germany.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

Mullen is led by an executive team with extensive EV, OEM and high-growth startup experience.

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working towards a sustainable future by creating a suite of clean-energy, electric vehicles at varied price points. With entirely US based manufacturing and operations, Mr. Michery is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.167, off by 20.2864%, on 2,048,767 volume. The average volume for the last 3 months is 27,255,326 and the stock's 52-week low/high is $0.1558/$141600000.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - How EVs Are Driving a Revolution in Automotive Design
• China's Renewable Energy Surge is a Wake-Up Call to the US
• US Senate Considers Scrapping EV Incentives Earlier Than Previously Planned

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

As Nevada's Walker Lane becomes a prime target for mineral exploration, Lahontan Gold (TSXV: LG) (OTCQB: LGCXF) is strategically positioned to capitalize, owning and developing four high-potential exploration properties in the area. "With a vision to evolve into Nevada's premier silver and gold producer, Lahontan has built a robust portfolio of assets across this geologically diverse and historically rich trend," reads a recent article. "The company controls four properties in the heart of Walker Lane: Santa Fe, West Santa Fe, Moho and Redlich. The company's flagship project, the Santa Fe Mine, is a 26.4 km2 past-producing, oxide-hosted gold-silver property. Between 1988 and 1995, Santa Fe produced 356,000 ounces of gold and 784,000 ounces of silver via open-pit mining and heap-leach processing. Since 2021, Lahontan has drilled 13,118 meters across 50 holes, contributing to a pit-constrained NI 43-101 resource estimate of 1.539 million indicated ounces and 0.411 million inferred ounces of gold equivalent."

To view the full article, visit https://ibn.fm/G5X62

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Wednesday's trading session at $0.0725, off by 0.4804392%, on 465,182 volume. The average volume for the last 3 months is 1,012,090 and the stock's 52-week low/high is $0.0143/$0.09049.

Recent News

• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) - RockBreaks - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Advances Portfolio in Walker Lane Hotspot
• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Drives Metallurgical Testing to Unlock Santa Fe Value
• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Set to Capitalize on Potential of Nevada's Walker Lane

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

• NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
• SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
• RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Wednesday's trading session at $0.7, up 108.9552%, on 6,213,924 volume. The average volume for the last 3 months is 28,174,632 and the stock's 52-week low/high is $0.2027/$3.89.

Recent News

• Calidi Biotherapeutics Inc. (NYSE American: CLDI) - InvestorNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 
• Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy
• BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Wednesday's trading session at $0.016, up 2.6958%, on 497,000 volume. The average volume for the last 3 months is 229,040 and the stock's 52-week low/high is $0.0053/$0.0571.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - TechMediaBreaks - Nightfood Holdings Inc. (NGTF) Eyes Opportunity at Intersection of Real Estate, Robotics, and AI
• TechMediaBreaks - Nightfood Holdings Inc. (NGTF) Poised to Disrupt Hospitality with AI and Automation
• Nightfood Holdings Inc. (NGTF) Embracing Tech Transformation in Hospitality